<DOC>
	<DOCNO>NCT00707746</DOCNO>
	<brief_summary>The purpose study determine safety efficacy mipomersen ( ISIS 301012 ) reduction total cholesterol , low density lipoprotein cholesterol ( LDL-C ) , apolipoprotein B ( apoB ) high risk subject intolerant statin .</brief_summary>
	<brief_title>Safety Efficacy Study ISIS 301012 ( Mipomersen ) Administration High Risk Statin Intolerant Subjects</brief_title>
	<detailed_description>In human , apoB principal apolipoprotein atherogenic lipoprotein , comprise low-density lipoprotein ( VLDL ) , intermediate density lipoprotein ( IDL ) low density lipoprotein ( LDL ) . ApoB messenger ribonucleic acid ( mRNA ) abundantly present liver . Within endoplasmatic reticulum , apoB require lipidation microsomal triglyceride transfer protein , allow apoB incorporate VLDL particle within lumen endoplasmatic reticulum . Non-lipidated apoB readily degrade via ubiquitination . Notably , apoB within VLDL particle obligatory hepatic secretion VLDL . ApoB remain present within VLDL-metabolism pathway , secretion clearance end product LDL liver LDL receptor . As consequence , apoB reliably reflect total burden atherogenic lipoprotein . Thus , apoB carry strong prognostic value cardiovascular event , exceeds predictive value LDL-C. Conversely , decrease level apoB ( e.g . familial hypobetalipoproteinemia ) associate reduced level atherosclerosis . These genetic observation prompt interest pharmacologic inhibition apoB synthesis . Mipomersen ( ISIS 301012 ) antisense drug target human apoB , principal apolipoprotein LDL metabolic precursor , VLDL . Mipomersen ( ISIS 301012 ) complementary cod region mRNA apoB , bind Watson Crick base pairing . The hybridization ( bind ) mipomersen ( ISIS 301012 ) cognate mRNA result Ribonuclease ( RNase ) H-mediated degradation cognate mRNA , thus inhibit translation apoB protein . This randomized , double-blind , placebo-controlled Phase 2 study ass safety efficacy mipomersen administration high-risk statin-intolerant patient hypercholesterolemia . This study consist ≤3-week screening period , 26 week treatment , 24-week post-treatment follow-up period . Eligible patient randomize 2:1 ratio receive mipomersen 200 mg matching volume placebo subcutaneous ( SC ) injection weekly . Following screen visit , eligible patient return study center clinical evaluation every week study drug administration assessment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Lipid Metabolism Disorders</mesh_term>
	<mesh_term>Mipomersen</mesh_term>
	<criteria>Diagnosis statin intolerance Diagnosis Coronary Artery Disease ( CAD ) Diagnosis hypercholesterolemia Stable weight &gt; 6 week Significant health problem recent past ( ≤24 week ) include heart attack , heart surgery , heart failure , uncontrolled hypothyroidism , blood disorder , digestive problem , disease central nervous system , cancer , liver renal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>statin intolerant</keyword>
	<keyword>hypercholesterolemia</keyword>
</DOC>